JPS6145776B2 - Specif combination analysis using prosthetic group as labelling component* reagent and composition for same* test kit* and ligand - Google Patents
Specif combination analysis using prosthetic group as labelling component* reagent and composition for same* test kit* and ligandInfo
- Publication number
- JPS6145776B2 JPS6145776B2 JP54077633A JP7763379A JPS6145776B2 JP S6145776 B2 JPS6145776 B2 JP S6145776B2 JP 54077633 A JP54077633 A JP 54077633A JP 7763379 A JP7763379 A JP 7763379A JP S6145776 B2 JPS6145776 B2 JP S6145776B2
- Authority
- JP
- Japan
- Prior art keywords
- binding
- complex
- liquid medium
- ligand
- apoenzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003446 ligand Substances 0.000 title claims description 30
- 238000004458 analytical method Methods 0.000 title claims description 26
- 238000002372 labelling Methods 0.000 title claims description 26
- 239000003153 chemical reaction reagent Substances 0.000 title description 8
- 238000012360 testing method Methods 0.000 title description 6
- 239000000203 mixture Substances 0.000 title description 3
- 238000009739 binding Methods 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108010006591 Apoenzymes Proteins 0.000 claims description 25
- 230000009870 specific binding Effects 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 108010025076 Holoenzymes Proteins 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 11
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical group C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 8
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 8
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 8
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 108010015776 Glucose oxidase Proteins 0.000 claims 5
- 239000004366 Glucose oxidase Substances 0.000 claims 5
- 229940116332 glucose oxidase Drugs 0.000 claims 5
- 235000019420 glucose oxidase Nutrition 0.000 claims 5
- 238000004737 colorimetric analysis Methods 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 241000894007 species Species 0.000 description 17
- 239000000126 substance Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 108010023603 Transcobalamins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- -1 for example Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Prostheses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91796178A | 1978-06-22 | 1978-06-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS552997A JPS552997A (en) | 1980-01-10 |
| JPS6145776B2 true JPS6145776B2 (en) | 1986-10-09 |
Family
ID=25439569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54077633A Expired JPS6145776B2 (en) | 1978-06-22 | 1979-06-21 | Specif combination analysis using prosthetic group as labelling component* reagent and composition for same* test kit* and ligand |
Country Status (21)
| Country | Link |
|---|---|
| JP (1) | JPS6145776B2 (no) |
| AR (1) | AR220947A1 (no) |
| AT (1) | AT363615B (no) |
| AU (1) | AU530673B2 (no) |
| BE (1) | BE877060A (no) |
| BR (1) | BR7903958A (no) |
| CH (1) | CH659713A5 (no) |
| DD (1) | DD144461A5 (no) |
| DE (1) | DE2924249C2 (no) |
| DK (1) | DK154670C (no) |
| ES (1) | ES481782A1 (no) |
| FI (1) | FI70726C (no) |
| FR (1) | FR2429258B1 (no) |
| GB (1) | GB2023607B (no) |
| IE (1) | IE48264B1 (no) |
| IL (1) | IL57570A (no) |
| LU (1) | LU81410A1 (no) |
| NL (1) | NL181527C (no) |
| NO (1) | NO154447C (no) |
| SE (1) | SE436522B (no) |
| ZA (1) | ZA793068B (no) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01159274U (no) * | 1988-03-31 | 1989-11-02 | ||
| JP2005528897A (ja) * | 2002-05-16 | 2005-09-29 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 不活化酵素を用いた方法および試薬システム |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1183450A (en) * | 1980-10-30 | 1985-03-05 | Alfred C. Greenquist | Homogeneous specific binding assay device and method |
| US4378428A (en) * | 1981-03-30 | 1983-03-29 | Baker Instruments Corporation | Method for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays |
| AU574646B2 (en) * | 1982-07-19 | 1988-07-14 | Cooperbiomedical Inc. | Enzyme assay method |
| US4550075A (en) * | 1983-06-22 | 1985-10-29 | Kallestad Laboratories, Inc. | Method for ligand determination utilizing an immunoassay monitorable by biotin-containing enzymes, and compositions therefor |
| SE466208B (sv) * | 1983-12-20 | 1992-01-13 | California Inst Of Techn | Enkelstraengad aminoderivat av oligonukleotider och foerfarande foer framstaellning daerav |
| GB8608435D0 (en) * | 1986-04-07 | 1986-05-14 | Cranfield Inst Of Tech | Specific binding assays |
| EP0274343A1 (en) * | 1987-01-06 | 1988-07-13 | IntraCel Corporation | A system of reactants involving an apo-enzyme useful in immunological analysis and a method for carrying out immunoassays with this system |
| US7759072B2 (en) | 2005-03-03 | 2010-07-20 | Sekisui Medical Co., Ltd. | Immunoassay method and reagent therefor |
| FR2889873B1 (fr) | 2005-08-18 | 2007-11-16 | Ceva Sante Animale Sa | Methode de detection de la progesterone dans le lait de vache et kit correspondant |
| EP3576129B1 (en) * | 2018-06-01 | 2023-05-03 | Thermo Fisher Scientific (Bremen) GmbH | Method for detecting the isotopic labelling state of unknown species of molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN142734B (no) * | 1975-04-28 | 1977-08-20 | Miles Lab |
-
1979
- 1979-06-15 IL IL57570A patent/IL57570A/xx unknown
- 1979-06-15 DE DE2924249A patent/DE2924249C2/de not_active Expired
- 1979-06-18 BE BE0/195807A patent/BE877060A/xx not_active IP Right Cessation
- 1979-06-18 FI FI791937A patent/FI70726C/fi not_active IP Right Cessation
- 1979-06-20 AU AU48230/79A patent/AU530673B2/en not_active Expired
- 1979-06-20 LU LU81410A patent/LU81410A1/xx unknown
- 1979-06-20 DD DD79213770A patent/DD144461A5/de unknown
- 1979-06-20 ZA ZA793068A patent/ZA793068B/xx unknown
- 1979-06-20 DK DK258079A patent/DK154670C/da not_active IP Right Cessation
- 1979-06-21 AT AT0438979A patent/AT363615B/de not_active IP Right Cessation
- 1979-06-21 SE SE7905514A patent/SE436522B/sv not_active IP Right Cessation
- 1979-06-21 NO NO792084A patent/NO154447C/no unknown
- 1979-06-21 JP JP54077633A patent/JPS6145776B2/ja not_active Expired
- 1979-06-21 GB GB7921693A patent/GB2023607B/en not_active Expired
- 1979-06-21 ES ES481782A patent/ES481782A1/es not_active Expired
- 1979-06-21 NL NLAANVRAGE7904879,A patent/NL181527C/xx not_active IP Right Cessation
- 1979-06-21 AR AR276993A patent/AR220947A1/es active
- 1979-06-21 CH CH5822/79A patent/CH659713A5/de not_active IP Right Cessation
- 1979-06-21 FR FR7915951A patent/FR2429258B1/fr not_active Expired
- 1979-06-22 BR BR7903958A patent/BR7903958A/pt unknown
- 1979-08-08 IE IE1156/79A patent/IE48264B1/en not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01159274U (no) * | 1988-03-31 | 1989-11-02 | ||
| JP2005528897A (ja) * | 2002-05-16 | 2005-09-29 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 不活化酵素を用いた方法および試薬システム |
| JP4656938B2 (ja) * | 2002-05-16 | 2011-03-23 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 不活化酵素を用いた方法および試薬システム |
Also Published As
| Publication number | Publication date |
|---|---|
| IE791156L (en) | 1979-12-22 |
| SE436522B (sv) | 1984-12-17 |
| NO154447C (no) | 1986-09-17 |
| FI70726B (fi) | 1986-06-26 |
| GB2023607B (en) | 1983-01-06 |
| FI791937A (fi) | 1979-12-23 |
| DK154670B (da) | 1988-12-05 |
| AU4823079A (en) | 1980-01-03 |
| BE877060A (fr) | 1979-10-15 |
| NO154447B (no) | 1986-06-09 |
| DD144461A5 (de) | 1980-10-15 |
| JPS552997A (en) | 1980-01-10 |
| BR7903958A (pt) | 1980-02-12 |
| DK258079A (da) | 1979-12-23 |
| FI70726C (fi) | 1986-10-06 |
| ZA793068B (en) | 1980-08-27 |
| AT363615B (de) | 1981-08-25 |
| CH659713A5 (de) | 1987-02-13 |
| IL57570A (en) | 1982-07-30 |
| DE2924249A1 (de) | 1980-01-03 |
| FR2429258B1 (fr) | 1985-03-29 |
| IL57570A0 (en) | 1979-10-31 |
| NO792084L (no) | 1979-12-28 |
| AU530673B2 (en) | 1983-07-28 |
| NL7904879A (nl) | 1979-12-28 |
| NL181527C (nl) | 1987-09-01 |
| ATA438979A (de) | 1981-01-15 |
| SE7905514L (sv) | 1979-12-23 |
| FR2429258A1 (fr) | 1980-01-18 |
| DE2924249C2 (de) | 1989-04-27 |
| IE48264B1 (en) | 1984-11-14 |
| GB2023607A (en) | 1980-01-03 |
| LU81410A1 (fr) | 1979-10-30 |
| DK154670C (da) | 1989-05-01 |
| AR220947A1 (es) | 1980-12-15 |
| ES481782A1 (es) | 1980-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kepner et al. | Fluorometric determination of calcium in blood serum. | |
| JPS5942454A (ja) | 液体中のハプテン又は抗原を分析するための均一系免疫分析方法及び試薬 | |
| JPS60242361A (ja) | 酸化還元酵素を用いる化学的分析法 | |
| US4921788A (en) | Competitive nucleic acid immunoassay for the detection of analytes | |
| JPH01145560A (ja) | 特異性均質免疫センサ装置 | |
| JPS6145776B2 (en) | Specif combination analysis using prosthetic group as labelling component* reagent and composition for same* test kit* and ligand | |
| CN106855572A (zh) | 一种胃泌素释放肽前体化学发光免疫检测试剂盒及其制备方法 | |
| Schroeder et al. | Immunochemiluminometric assay for hepatitis B surface antigen. | |
| CN109239367A (zh) | 测定小分子化合物的方法及试剂盒 | |
| EP0840895B1 (en) | Methods of obtaining receptor:release ligand (reland) complexes and test assays | |
| EP0155224A2 (en) | Solid-borne complex bearing chromagen responsive functionality for antibody, antigen, receptor, or ligand detection | |
| Zhao et al. | Multiple chemiluminescence immunoassay detection of the concentration ratio of glycosylated hemoglobin A1c to total hemoglobin in whole blood samples | |
| CN110196334A (zh) | 血栓调节蛋白化学发光免疫定量检测试剂盒及其制备方法 | |
| Wang et al. | Development of a highly sensitive and selective microplate chemiluminescence enzyme immunoassay for the determination of free thyroxine in human serum | |
| Faatz et al. | Automated Immunoassays for the detection of biomarkers in body fluids | |
| US4340668A (en) | Heme-labeled specific binding assay | |
| CN1217193C (zh) | 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法 | |
| Wang et al. | Immunoassay by graphite furnace atomic absorption spectrometry using a metal chelate as a label | |
| Broyles et al. | Drug antibody measurement by homogeneous enzyme immunoassay with amperometric detection | |
| CN110618261A (zh) | 一种定量检测地高辛的化学发光免疫检测试剂盒及其制备方法 | |
| CN111443203A (zh) | 11-脱氢血栓烷b2均相酶免疫检测试剂盒及其制备方法 | |
| Voshall et al. | Effect of albumin on serum digoxin radioimmunoassays | |
| Helsingius et al. | Solid-phase immunoassay of digoxin by measuring time-resolved fluorescence. | |
| HU228077B1 (en) | Cobalamin assay | |
| Schölmerich et al. | [19] Immobilized enzymes for assaying bile acids |